Company intelligence / Profile preview

ZYTOMICS

Ownership: Private
Employees: ~170
Development stage: Commercial

Overview

ZYTOMICS provides commercialized reagents, automation systems, and analytics for clinical cancer diagnostics with a focus on immunohistochemistry (IHC), in situ hybridization (ISH), and next-generation sequencing. The company holds IVDR certification for over 150 ISH products. Their solutions are widely adopted across Europe with global distribution to more than 90 countries.

Modalities: AntibodyProbe
Industry: Pathology

Beyond the preview

Go deeper on ZYTOMICS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZYTOMICS.

Explore the full profile